AU2011307691A1 - Peptides from the venom of the Rhopalurus junceus scorpion and pharmaceutical composition - Google Patents
Peptides from the venom of the Rhopalurus junceus scorpion and pharmaceutical composition Download PDFInfo
- Publication number
- AU2011307691A1 AU2011307691A1 AU2011307691A AU2011307691A AU2011307691A1 AU 2011307691 A1 AU2011307691 A1 AU 2011307691A1 AU 2011307691 A AU2011307691 A AU 2011307691A AU 2011307691 A AU2011307691 A AU 2011307691A AU 2011307691 A1 AU2011307691 A1 AU 2011307691A1
- Authority
- AU
- Australia
- Prior art keywords
- venom
- junceus
- scorpion
- tumor
- cells
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 239000008194 pharmaceutical composition Substances 0.000 title claims description 5
- 239000002435 venom Substances 0.000 title abstract description 81
- 231100000611 venom Toxicity 0.000 title abstract description 81
- 210000001048 venom Anatomy 0.000 title abstract description 81
- 241001050861 Rhopalurus junceus Species 0.000 title abstract description 58
- 108090000765 processed proteins & peptides Proteins 0.000 title abstract description 22
- 102000004196 processed proteins & peptides Human genes 0.000 title abstract description 17
- 239000000203 mixture Substances 0.000 claims abstract description 29
- 238000009472 formulation Methods 0.000 claims abstract description 17
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 8
- 239000012153 distilled water Substances 0.000 claims description 6
- 230000000699 topical effect Effects 0.000 claims description 2
- 239000000443 aerosol Substances 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 abstract description 35
- 201000011510 cancer Diseases 0.000 abstract description 18
- 102000004169 proteins and genes Human genes 0.000 abstract description 17
- 108090000623 proteins and genes Proteins 0.000 abstract description 17
- 230000000202 analgesic effect Effects 0.000 abstract description 11
- 230000003110 anti-inflammatory effect Effects 0.000 abstract description 8
- 229940079593 drug Drugs 0.000 abstract description 5
- 239000003814 drug Substances 0.000 abstract description 5
- 150000001413 amino acids Chemical class 0.000 abstract description 4
- 230000003217 anti-cancerogenic effect Effects 0.000 abstract description 3
- 150000001720 carbohydrates Chemical class 0.000 abstract description 3
- 235000014633 carbohydrates Nutrition 0.000 abstract description 3
- 150000002632 lipids Chemical class 0.000 abstract description 3
- 150000003839 salts Chemical class 0.000 abstract description 2
- 150000002500 ions Chemical class 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 description 38
- 239000002795 scorpion venom Substances 0.000 description 31
- 230000000694 effects Effects 0.000 description 29
- 241000699670 Mus sp. Species 0.000 description 27
- 241001465754 Metazoa Species 0.000 description 23
- 230000005764 inhibitory process Effects 0.000 description 22
- 238000003556 assay Methods 0.000 description 20
- 210000004881 tumor cell Anatomy 0.000 description 20
- 230000004614 tumor growth Effects 0.000 description 19
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 18
- 241000239226 Scorpiones Species 0.000 description 15
- 230000004083 survival effect Effects 0.000 description 15
- 238000011156 evaluation Methods 0.000 description 14
- 238000000034 method Methods 0.000 description 14
- 239000000243 solution Substances 0.000 description 14
- 239000003053 toxin Substances 0.000 description 14
- 231100000765 toxin Toxicity 0.000 description 14
- 108700012359 toxins Proteins 0.000 description 14
- 239000002356 single layer Substances 0.000 description 13
- 206010018691 Granuloma Diseases 0.000 description 12
- 241001529936 Murinae Species 0.000 description 12
- 238000007912 intraperitoneal administration Methods 0.000 description 12
- 238000011282 treatment Methods 0.000 description 12
- 206010061218 Inflammation Diseases 0.000 description 11
- 239000000047 product Substances 0.000 description 11
- 239000000126 substance Substances 0.000 description 11
- 230000004054 inflammatory process Effects 0.000 description 10
- 210000004072 lung Anatomy 0.000 description 10
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 9
- 239000013642 negative control Substances 0.000 description 9
- 206010018338 Glioma Diseases 0.000 description 8
- 206010030113 Oedema Diseases 0.000 description 8
- 238000010171 animal model Methods 0.000 description 8
- 230000000259 anti-tumor effect Effects 0.000 description 8
- OROGSEYTTFOCAN-DNJOTXNNSA-N codeine Chemical compound C([C@H]1[C@H](N(CC[C@@]112)C)C3)=C[C@H](O)[C@@H]1OC1=C2C3=CC=C1OC OROGSEYTTFOCAN-DNJOTXNNSA-N 0.000 description 8
- 229940117173 croton oil Drugs 0.000 description 8
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 8
- 229960003957 dexamethasone Drugs 0.000 description 8
- 238000000338 in vitro Methods 0.000 description 8
- 206010027476 Metastases Diseases 0.000 description 7
- 208000002193 Pain Diseases 0.000 description 7
- 230000009401 metastasis Effects 0.000 description 7
- 239000013641 positive control Substances 0.000 description 7
- 238000000746 purification Methods 0.000 description 7
- 230000002829 reductive effect Effects 0.000 description 7
- 101710164760 Chlorotoxin Proteins 0.000 description 6
- 230000003187 abdominal effect Effects 0.000 description 6
- QPAKKWCQMHUHNI-GQIQPHNSSA-N chlorotoxin Chemical compound C([C@H]1C(=O)NCC(=O)N2CCC[C@H]2C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H]2CSSC[C@H]3C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H]4CSSC[C@@H](C(N[C@@H](CCSC)C(=O)N5CCC[C@H]5C(=O)N[C@@H](CSSC[C@@H](C(=O)N1)NC(=O)[C@H](CCCCN)NC(=O)CNC(=O)[C@H](CCCNC(N)=N)NC(=O)CNC(=O)[C@H](CCCCN)NC(=O)CNC(=O)CNC(=O)[C@H](CSSC[C@H](NC(=O)[C@H](CC(C)C)NC2=O)C(=O)N[C@@H](CCCNC(N)=N)C(N)=O)NC4=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1N=CNC=1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N3)=O)NC(=O)[C@@H](N)CCSC)C1=CC=C(O)C=C1 QPAKKWCQMHUHNI-GQIQPHNSSA-N 0.000 description 6
- 229960005534 chlorotoxin Drugs 0.000 description 6
- 238000004519 manufacturing process Methods 0.000 description 6
- 230000036407 pain Effects 0.000 description 6
- 230000000144 pharmacologic effect Effects 0.000 description 6
- 230000009467 reduction Effects 0.000 description 6
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 5
- 229960001138 acetylsalicylic acid Drugs 0.000 description 5
- 230000006907 apoptotic process Effects 0.000 description 5
- 201000008274 breast adenocarcinoma Diseases 0.000 description 5
- 230000001472 cytotoxic effect Effects 0.000 description 5
- 231100000673 dose–response relationship Toxicity 0.000 description 5
- 238000002513 implantation Methods 0.000 description 5
- 230000006872 improvement Effects 0.000 description 5
- 238000003819 low-pressure liquid chromatography Methods 0.000 description 5
- 239000002609 medium Substances 0.000 description 5
- 239000008188 pellet Substances 0.000 description 5
- 230000008569 process Effects 0.000 description 5
- 230000004044 response Effects 0.000 description 5
- 239000000725 suspension Substances 0.000 description 5
- 210000001519 tissue Anatomy 0.000 description 5
- 238000011200 topical administration Methods 0.000 description 5
- 230000001988 toxicity Effects 0.000 description 5
- 231100000419 toxicity Toxicity 0.000 description 5
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 4
- 206010008342 Cervix carcinoma Diseases 0.000 description 4
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 4
- 102000004190 Enzymes Human genes 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 4
- 208000032612 Glial tumor Diseases 0.000 description 4
- 241001481692 Mesobuthus martensii Species 0.000 description 4
- 241000700159 Rattus Species 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 238000002835 absorbance Methods 0.000 description 4
- 230000033115 angiogenesis Effects 0.000 description 4
- YZXBAPSDXZZRGB-DOFZRALJSA-N arachidonic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O YZXBAPSDXZZRGB-DOFZRALJSA-N 0.000 description 4
- 239000012298 atmosphere Substances 0.000 description 4
- 210000004556 brain Anatomy 0.000 description 4
- 235000012730 carminic acid Nutrition 0.000 description 4
- 210000003169 central nervous system Anatomy 0.000 description 4
- 208000019065 cervical carcinoma Diseases 0.000 description 4
- 229960004126 codeine Drugs 0.000 description 4
- 231100000433 cytotoxic Toxicity 0.000 description 4
- 230000003013 cytotoxicity Effects 0.000 description 4
- 231100000135 cytotoxicity Toxicity 0.000 description 4
- 210000005069 ears Anatomy 0.000 description 4
- 229940088598 enzyme Drugs 0.000 description 4
- OROGSEYTTFOCAN-UHFFFAOYSA-N hydrocodone Natural products C1C(N(CCC234)C)C2C=CC(O)C3OC2=C4C1=CC=C2OC OROGSEYTTFOCAN-UHFFFAOYSA-N 0.000 description 4
- 230000003040 nociceptive effect Effects 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- 206010067484 Adverse reaction Diseases 0.000 description 3
- 206010006187 Breast cancer Diseases 0.000 description 3
- 201000009030 Carcinoma Diseases 0.000 description 3
- 229920000742 Cotton Polymers 0.000 description 3
- 206010039491 Sarcoma Diseases 0.000 description 3
- 230000006838 adverse reaction Effects 0.000 description 3
- 229940035676 analgesics Drugs 0.000 description 3
- 239000000730 antalgic agent Substances 0.000 description 3
- 230000003502 anti-nociceptive effect Effects 0.000 description 3
- 230000003078 antioxidant effect Effects 0.000 description 3
- 230000004071 biological effect Effects 0.000 description 3
- 230000008033 biological extinction Effects 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 210000000481 breast Anatomy 0.000 description 3
- 238000004113 cell culture Methods 0.000 description 3
- 230000010261 cell growth Effects 0.000 description 3
- 230000004663 cell proliferation Effects 0.000 description 3
- 210000001072 colon Anatomy 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 230000007717 exclusion Effects 0.000 description 3
- 238000002270 exclusion chromatography Methods 0.000 description 3
- 210000002950 fibroblast Anatomy 0.000 description 3
- 230000012010 growth Effects 0.000 description 3
- 230000002489 hematologic effect Effects 0.000 description 3
- 238000011141 high resolution liquid chromatography Methods 0.000 description 3
- 230000002757 inflammatory effect Effects 0.000 description 3
- 210000003292 kidney cell Anatomy 0.000 description 3
- 230000003902 lesion Effects 0.000 description 3
- 201000005296 lung carcinoma Diseases 0.000 description 3
- 210000004698 lymphocyte Anatomy 0.000 description 3
- 239000003550 marker Substances 0.000 description 3
- 210000003097 mucus Anatomy 0.000 description 3
- FRZJZRVZZNTMAW-UHFFFAOYSA-N n,n-diethyl-3-(hydroxymethyl)benzamide Chemical compound CCN(CC)C(=O)C1=CC=CC(CO)=C1 FRZJZRVZZNTMAW-UHFFFAOYSA-N 0.000 description 3
- 210000000496 pancreas Anatomy 0.000 description 3
- 239000000546 pharmaceutical excipient Substances 0.000 description 3
- 230000003389 potentiating effect Effects 0.000 description 3
- 230000003244 pro-oxidative effect Effects 0.000 description 3
- 210000002307 prostate Anatomy 0.000 description 3
- 238000012216 screening Methods 0.000 description 3
- 230000035945 sensitivity Effects 0.000 description 3
- 238000000926 separation method Methods 0.000 description 3
- 241000894007 species Species 0.000 description 3
- 230000000638 stimulation Effects 0.000 description 3
- 230000008961 swelling Effects 0.000 description 3
- 238000005303 weighing Methods 0.000 description 3
- 241000238421 Arthropoda Species 0.000 description 2
- 241000283690 Bos taurus Species 0.000 description 2
- 108010062745 Chloride Channels Proteins 0.000 description 2
- 102000011045 Chloride Channels Human genes 0.000 description 2
- 241000282552 Chlorocebus aethiops Species 0.000 description 2
- 206010011224 Cough Diseases 0.000 description 2
- 230000005778 DNA damage Effects 0.000 description 2
- 231100000277 DNA damage Toxicity 0.000 description 2
- 240000001624 Espostoa lanata Species 0.000 description 2
- 235000009161 Espostoa lanata Nutrition 0.000 description 2
- 201000008808 Fibrosarcoma Diseases 0.000 description 2
- 241000239268 Leiurus quinquestriatus Species 0.000 description 2
- 206010027458 Metastases to lung Diseases 0.000 description 2
- 206010061309 Neoplasm progression Diseases 0.000 description 2
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 2
- 101710099833 Venom protein Proteins 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 239000008186 active pharmaceutical agent Substances 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 230000036592 analgesia Effects 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 239000002260 anti-inflammatory agent Substances 0.000 description 2
- 230000001028 anti-proliverative effect Effects 0.000 description 2
- 229940114079 arachidonic acid Drugs 0.000 description 2
- 235000021342 arachidonic acid Nutrition 0.000 description 2
- 235000010323 ascorbic acid Nutrition 0.000 description 2
- 229960005070 ascorbic acid Drugs 0.000 description 2
- 239000011668 ascorbic acid Substances 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- BPLKXBNWXRMHRE-UHFFFAOYSA-N copper;1,10-phenanthroline Chemical compound [Cu].C1=CN=C2C3=NC=CC=C3C=CC2=C1 BPLKXBNWXRMHRE-UHFFFAOYSA-N 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 230000008034 disappearance Effects 0.000 description 2
- 230000001605 fetal effect Effects 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 238000013467 fragmentation Methods 0.000 description 2
- 238000006062 fragmentation reaction Methods 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N iron Substances [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- 229910052742 iron Inorganic materials 0.000 description 2
- 230000009191 jumping Effects 0.000 description 2
- 231100000053 low toxicity Toxicity 0.000 description 2
- 201000005202 lung cancer Diseases 0.000 description 2
- 208000020816 lung neoplasm Diseases 0.000 description 2
- 238000004949 mass spectrometry Methods 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 210000004498 neuroglial cell Anatomy 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- 238000003359 percent control normalization Methods 0.000 description 2
- 210000003024 peritoneal macrophage Anatomy 0.000 description 2
- 238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 2
- 230000002685 pulmonary effect Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 2
- 238000001228 spectrum Methods 0.000 description 2
- 210000000952 spleen Anatomy 0.000 description 2
- 230000002269 spontaneous effect Effects 0.000 description 2
- 230000006641 stabilisation Effects 0.000 description 2
- 238000011105 stabilization Methods 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 125000003831 tetrazolyl group Chemical group 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 231100000027 toxicology Toxicity 0.000 description 2
- 230000005751 tumor progression Effects 0.000 description 2
- OVJBOPBBHWOWJI-FYNXUGHNSA-N (2S)-2-[[(2S)-1-[(2S)-2-[[(aS,1R,3aS,4S,10S,16S,19R,22S,25S,28S,34S,37S,40R,45R,48S,51S,57S,60S,63S,69S,72S,75S,78S,85R,88S,91R,94S)-40-[[(2S)-6-amino-2-[[(2S)-2-[[(2S)-4-amino-2-[[(2S,3S)-2-[[(2S,3S)-2-[[(2S,3R)-2-amino-3-hydroxybutanoyl]amino]-3-methylpentanoyl]amino]-3-methylpentanoyl]amino]-4-oxobutanoyl]amino]-3-methylbutanoyl]amino]hexanoyl]amino]-25,48,78,88,94-pentakis(4-aminobutyl)-a-(2-amino-2-oxoethyl)-22,63,72-tris(3-amino-3-oxopropyl)-69-benzyl-37-[(1R)-1-hydroxyethyl]-34,60-bis(hydroxymethyl)-51,57,75-trimethyl-16-(2-methylpropyl)-3a-(2-methylsulfanylethyl)-2a,3,5a,9,15,18,21,24,27,33,36,39,47,50,53,56,59,62,65,68,71,74,77,80,87,90,93,96,99-nonacosaoxo-7a,8a,42,43,82,83-hexathia-1a,2,4a,8,14,17,20,23,26,32,35,38,46,49,52,55,58,61,64,67,70,73,76,79,86,89,92,95,98-nonacosazahexacyclo[43.35.25.419,91.04,8.010,14.028,32]nonahectane-85-carbonyl]amino]-3-(4-hydroxyphenyl)propanoyl]pyrrolidine-2-carbonyl]amino]-3-(1H-imidazol-5-yl)propanoic acid Chemical compound CC[C@H](C)[C@H](NC(=O)[C@@H](N)[C@@H](C)O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@H]1CSSC[C@@H]2NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](Cc3ccccc3)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCCN)NC(=O)[C@@H]3CSSC[C@H](NC(=O)[C@H](CCCCN)NC(=O)[C@H](CSSC[C@H](NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@@H]4CCCN4C(=O)[C@H](CO)NC(=O)[C@@H](NC1=O)[C@@H](C)O)C(=O)N[C@@H](CC(C)C)C(=O)N1CCC[C@H]1C(=O)N1CCC[C@H]1C(=O)N3)NC(=O)[C@H](CCCCN)NC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCSC)NC2=O)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N1CCC[C@H]1C(=O)N[C@@H](Cc1cnc[nH]1)C(O)=O OVJBOPBBHWOWJI-FYNXUGHNSA-N 0.000 description 1
- XMTQQYYKAHVGBJ-UHFFFAOYSA-N 3-(3,4-DICHLOROPHENYL)-1,1-DIMETHYLUREA Chemical compound CN(C)C(=O)NC1=CC=C(Cl)C(Cl)=C1 XMTQQYYKAHVGBJ-UHFFFAOYSA-N 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- USFZMSVCRYTOJT-UHFFFAOYSA-N Ammonium acetate Chemical compound N.CC(O)=O USFZMSVCRYTOJT-UHFFFAOYSA-N 0.000 description 1
- 239000005695 Ammonium acetate Substances 0.000 description 1
- 241000239223 Arachnida Species 0.000 description 1
- 208000003174 Brain Neoplasms Diseases 0.000 description 1
- 201000011057 Breast sarcoma Diseases 0.000 description 1
- 241000239225 Buthidae Species 0.000 description 1
- 229910002975 Cd Pb Inorganic materials 0.000 description 1
- 101000997261 Centruroides margaritatus Potassium channel toxin alpha-KTx 2.2 Proteins 0.000 description 1
- 241000699802 Cricetulus griseus Species 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- 101000761020 Dinoponera quadriceps Poneritoxin Proteins 0.000 description 1
- 208000000059 Dyspnea Diseases 0.000 description 1
- 206010013975 Dyspnoeas Diseases 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 206010015548 Euthanasia Diseases 0.000 description 1
- 208000009331 Experimental Sarcoma Diseases 0.000 description 1
- 206010015866 Extravasation Diseases 0.000 description 1
- 206010053759 Growth retardation Diseases 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 206010022998 Irritability Diseases 0.000 description 1
- 208000031671 Large B-Cell Diffuse Lymphoma Diseases 0.000 description 1
- 206010023856 Laryngeal squamous cell carcinoma Diseases 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- 102100037611 Lysophospholipase Human genes 0.000 description 1
- 231100000002 MTT assay Toxicity 0.000 description 1
- 238000000134 MTT assay Methods 0.000 description 1
- 102000000424 Matrix Metalloproteinase 2 Human genes 0.000 description 1
- 108010016165 Matrix Metalloproteinase 2 Proteins 0.000 description 1
- 101000716700 Mesobuthus martensii Toxin BmKT Proteins 0.000 description 1
- 229910003110 Mg K Inorganic materials 0.000 description 1
- 238000011785 NMRI mouse Methods 0.000 description 1
- 206010029260 Neuroblastoma Diseases 0.000 description 1
- 108091002531 OF-1 protein Proteins 0.000 description 1
- 108020002230 Pancreatic Ribonuclease Proteins 0.000 description 1
- 102000005891 Pancreatic ribonuclease Human genes 0.000 description 1
- 108010058864 Phospholipases A2 Proteins 0.000 description 1
- 239000004793 Polystyrene Substances 0.000 description 1
- 102000004257 Potassium Channel Human genes 0.000 description 1
- 101800004937 Protein C Proteins 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 241000273008 Rhopalurus Species 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 101800001700 Saposin-D Proteins 0.000 description 1
- 102400000827 Saposin-D Human genes 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- CSCPPACGZOOCGX-UHFFFAOYSA-N acetone Substances CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 208000038016 acute inflammation Diseases 0.000 description 1
- 230000006022 acute inflammation Effects 0.000 description 1
- 208000005298 acute pain Diseases 0.000 description 1
- 230000007059 acute toxicity Effects 0.000 description 1
- 231100000403 acute toxicity Toxicity 0.000 description 1
- 208000009956 adenocarcinoma Diseases 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 238000000246 agarose gel electrophoresis Methods 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 235000019257 ammonium acetate Nutrition 0.000 description 1
- 229940043376 ammonium acetate Drugs 0.000 description 1
- 210000003484 anatomy Anatomy 0.000 description 1
- 230000002491 angiogenic effect Effects 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 229940124599 anti-inflammatory drug Drugs 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 238000011088 calibration curve Methods 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 230000004709 cell invasion Effects 0.000 description 1
- 230000012292 cell migration Effects 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 239000013043 chemical agent Substances 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 239000013611 chromosomal DNA Substances 0.000 description 1
- 208000037976 chronic inflammation Diseases 0.000 description 1
- 230000006020 chronic inflammation Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 230000000994 depressogenic effect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000002405 diagnostic procedure Methods 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 230000002500 effect on skin Effects 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- 239000003797 essential amino acid Substances 0.000 description 1
- 235000020776 essential amino acid Nutrition 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 230000036251 extravasation Effects 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 235000012631 food intake Nutrition 0.000 description 1
- 238000001502 gel electrophoresis Methods 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 230000033687 granuloma formation Effects 0.000 description 1
- 230000009036 growth inhibition Effects 0.000 description 1
- 231100000001 growth retardation Toxicity 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 229910001385 heavy metal Inorganic materials 0.000 description 1
- 230000001632 homeopathic effect Effects 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000005917 in vivo anti-tumor Effects 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 230000004968 inflammatory condition Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 239000002919 insect venom Substances 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- FBAFATDZDUQKNH-UHFFFAOYSA-M iron chloride Chemical compound [Cl-].[Fe] FBAFATDZDUQKNH-UHFFFAOYSA-M 0.000 description 1
- 230000002262 irrigation Effects 0.000 description 1
- 238000003973 irrigation Methods 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 210000000867 larynx Anatomy 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 210000003141 lower extremity Anatomy 0.000 description 1
- 201000003711 lung mucoepidermoid carcinoma Diseases 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 229910021645 metal ion Inorganic materials 0.000 description 1
- 230000002438 mitochondrial effect Effects 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000009456 molecular mechanism Effects 0.000 description 1
- 229940105132 myristate Drugs 0.000 description 1
- VMGAPWLDMVPYIA-HIDZBRGKSA-N n'-amino-n-iminomethanimidamide Chemical compound N\N=C\N=N VMGAPWLDMVPYIA-HIDZBRGKSA-N 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 230000004770 neurodegeneration Effects 0.000 description 1
- 208000015122 neurodegenerative disease Diseases 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
- FEMOMIGRRWSMCU-UHFFFAOYSA-N ninhydrin Chemical compound C1=CC=C2C(=O)C(O)(O)C(=O)C2=C1 FEMOMIGRRWSMCU-UHFFFAOYSA-N 0.000 description 1
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 1
- 210000004882 non-tumor cell Anatomy 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 238000011275 oncology therapy Methods 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 230000008533 pain sensitivity Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 210000004303 peritoneum Anatomy 0.000 description 1
- 238000005502 peroxidation Methods 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 230000007096 poisonous effect Effects 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 229920002223 polystyrene Polymers 0.000 description 1
- 108020001213 potassium channel Proteins 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000000770 proinflammatory effect Effects 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 229960000856 protein c Drugs 0.000 description 1
- 208000010568 pulmonary mucoepidermoid carcinoma Diseases 0.000 description 1
- 230000035484 reaction time Effects 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 210000000664 rectum Anatomy 0.000 description 1
- BOLDJAUMGUJJKM-LSDHHAIUSA-N renifolin D Natural products CC(=C)[C@@H]1Cc2c(O)c(O)ccc2[C@H]1CC(=O)c3ccc(O)cc3O BOLDJAUMGUJJKM-LSDHHAIUSA-N 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 230000008458 response to injury Effects 0.000 description 1
- 201000006845 reticulosarcoma Diseases 0.000 description 1
- 208000029922 reticulum cell sarcoma Diseases 0.000 description 1
- 230000009834 selective interaction Effects 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000013222 sprague-dawley male rat Methods 0.000 description 1
- 238000012453 sprague-dawley rat model Methods 0.000 description 1
- 230000007480 spreading Effects 0.000 description 1
- 238000003892 spreading Methods 0.000 description 1
- 239000008174 sterile solution Substances 0.000 description 1
- 230000003637 steroidlike Effects 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 231100001257 subchronic oral toxicity Toxicity 0.000 description 1
- 230000007666 subchronic toxicity Effects 0.000 description 1
- 231100000195 subchronic toxicity Toxicity 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- TUNFSRHWOTWDNC-UHFFFAOYSA-N tetradecanoic acid Chemical compound CCCCCCCCCCCCCC(O)=O TUNFSRHWOTWDNC-UHFFFAOYSA-N 0.000 description 1
- WROMPOXWARCANT-UHFFFAOYSA-N tfa trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.OC(=O)C(F)(F)F WROMPOXWARCANT-UHFFFAOYSA-N 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 238000002723 toxicity assay Methods 0.000 description 1
- 231100000041 toxicology testing Toxicity 0.000 description 1
- 230000004565 tumor cell growth Effects 0.000 description 1
- 238000002211 ultraviolet spectrum Methods 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 230000008728 vascular permeability Effects 0.000 description 1
- 230000007998 vessel formation Effects 0.000 description 1
- 230000004584 weight gain Effects 0.000 description 1
- 235000019786 weight gain Nutrition 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/43504—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
- C07K14/43513—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from arachnidae
- C07K14/43522—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from arachnidae from scorpions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/63—Arthropods
- A61K35/646—Arachnids, e.g. spiders, scorpions, ticks or mites
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1767—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Insects & Arthropods (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Tropical Medicine & Parasitology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Zoology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biophysics (AREA)
- Toxicology (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CU2010000186A CU24055B1 (es) | 2010-09-27 | 2010-09-27 | Composiciones farmacéuticas de veneno de escorpión rhopalurus junceus |
| CU2010-0186 | 2010-09-27 | ||
| PCT/CU2011/000006 WO2012041261A2 (es) | 2010-09-27 | 2011-09-27 | Peptidos del veneno de escorpion rhopalorus junceus y composicion farmaceutica |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AU2011307691A1 true AU2011307691A1 (en) | 2013-05-02 |
Family
ID=45566782
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2011307691A Abandoned AU2011307691A1 (en) | 2010-09-27 | 2011-09-27 | Peptides from the venom of the Rhopalurus junceus scorpion and pharmaceutical composition |
Country Status (17)
| Country | Link |
|---|---|
| EP (1) | EP2623111A2 (enExample) |
| JP (1) | JP2013542196A (enExample) |
| KR (1) | KR20140041381A (enExample) |
| CN (1) | CN103200951A (enExample) |
| AP (1) | AP2013006811A0 (enExample) |
| AR (1) | AR083117A1 (enExample) |
| AU (1) | AU2011307691A1 (enExample) |
| BR (1) | BR112013007198A2 (enExample) |
| CA (1) | CA2812841A1 (enExample) |
| CO (1) | CO6781464A2 (enExample) |
| CU (1) | CU24055B1 (enExample) |
| EC (1) | ECSP13012595A (enExample) |
| IL (1) | IL225577A0 (enExample) |
| MX (1) | MX360726B (enExample) |
| RU (1) | RU2563348C2 (enExample) |
| SG (1) | SG191708A1 (enExample) |
| WO (1) | WO2012041261A2 (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103074304B (zh) * | 2013-01-28 | 2016-01-13 | 江苏健安生物科技有限公司 | 高水平人二倍体细胞培养水痘-带状疱疹疫苗病毒方法 |
| MX2019000570A (es) * | 2018-12-19 | 2020-08-13 | Centro De Investig Biologicas Del Noroeste S C | Composición homeopatica a base de veneno de escorpión rhopalurus junceus y su uso en acuicultura. |
| EP4267251A4 (en) * | 2020-12-22 | 2024-12-18 | Preveceutical Medical Inc. | CYCLIC PEPTIDES AND USES THEREOF |
| CN113384682B (zh) * | 2021-05-31 | 2023-07-04 | 南方医科大学 | 蝎毒多肽Smp43在制备抗肿瘤药物的应用 |
| CN117069800B (zh) * | 2023-10-16 | 2023-12-12 | 山东省食品药品检验研究院 | 一种鉴别东亚钳蝎的特征多肽及其应用 |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1030229C (zh) | 1991-12-16 | 1995-11-08 | 山东省蒙阴县酒厂 | 全蝎酒的制作方法 |
| CN1076858A (zh) | 1993-03-24 | 1993-10-06 | 王强华 | 熊胆全蝎酒及其制备工艺 |
| CU22413A1 (es) | 1994-01-11 | 1996-01-31 | Composicion antitumoral | |
| US5905027A (en) | 1995-12-27 | 1999-05-18 | Uab Research Foundation | Method of diagnosing and treating gliomas |
| FR2745004B1 (fr) * | 1996-02-16 | 1998-03-27 | Rhone Poulenc Agrochimie | Peptide antibacterien et antifongique |
| US6168651B1 (en) | 1998-10-08 | 2001-01-02 | Donaldson Company, Inc. | Filter assembly with shaped adsorbent article; and devices and methods of use |
| CN1279088A (zh) | 1999-06-25 | 2001-01-10 | 谷令旗 | 一种治疗肝癌药剂的制备方法 |
| CN1265901A (zh) | 2000-01-26 | 2000-09-13 | 徐忠廷 | 一种抗癌中药丸剂 |
| CN1316249A (zh) | 2001-04-04 | 2001-10-10 | 李滋星 | 全蝎活性营养液 |
| CN1157215C (zh) | 2001-07-30 | 2004-07-14 | 张官锁 | 一种治疗癌症的中药组合物 |
| CN1325514C (zh) * | 2001-09-30 | 2007-07-11 | 沈阳药科大学 | 蝎镇痛抗肿瘤缬精甘肽及获得方法 |
| CN100465272C (zh) * | 2002-01-18 | 2009-03-04 | 中国科学院上海有机化学研究所 | 重组东亚马氏钳蝎毒rBmKaIT1的基因工程 |
| WO2003101475A1 (en) * | 2002-05-31 | 2003-12-11 | Transmolecular Inc. | Treatment of cell proliferative disorders with chlorotoxin |
| CN1256971C (zh) | 2002-08-12 | 2006-05-24 | 徐继康 | 一种用于治疗肿瘤的中药胶囊 |
| US8097284B2 (en) * | 2007-11-13 | 2012-01-17 | Arthur Mikaelian | Polarized scorpion venom solution and a method for making polarized scorpion venom solution |
-
2010
- 2010-09-27 CU CU2010000186A patent/CU24055B1/es not_active IP Right Cessation
-
2011
- 2011-09-27 AP AP2013006811A patent/AP2013006811A0/xx unknown
- 2011-09-27 MX MX2013003545A patent/MX360726B/es active IP Right Grant
- 2011-09-27 AR ARP110103520A patent/AR083117A1/es not_active Application Discontinuation
- 2011-09-27 EP EP11815845.0A patent/EP2623111A2/en not_active Withdrawn
- 2011-09-27 JP JP2013530559A patent/JP2013542196A/ja active Pending
- 2011-09-27 RU RU2013119431/10A patent/RU2563348C2/ru active IP Right Revival
- 2011-09-27 KR KR1020137010868A patent/KR20140041381A/ko not_active Ceased
- 2011-09-27 SG SG2013022850A patent/SG191708A1/en unknown
- 2011-09-27 CA CA2812841A patent/CA2812841A1/en not_active Abandoned
- 2011-09-27 CN CN2011800541685A patent/CN103200951A/zh active Pending
- 2011-09-27 BR BR112013007198A patent/BR112013007198A2/pt not_active IP Right Cessation
- 2011-09-27 WO PCT/CU2011/000006 patent/WO2012041261A2/es not_active Ceased
- 2011-09-27 AU AU2011307691A patent/AU2011307691A1/en not_active Abandoned
-
2013
- 2013-04-04 IL IL225577A patent/IL225577A0/en unknown
- 2013-04-25 CO CO13105491A patent/CO6781464A2/es not_active Application Discontinuation
- 2013-04-29 EC ECSP13012595 patent/ECSP13012595A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| JP2013542196A (ja) | 2013-11-21 |
| KR20140041381A (ko) | 2014-04-04 |
| AP2013006811A0 (en) | 2013-04-30 |
| EP2623111A2 (en) | 2013-08-07 |
| SG191708A1 (en) | 2013-08-30 |
| CN103200951A (zh) | 2013-07-10 |
| ECSP13012595A (es) | 2014-11-28 |
| RU2563348C2 (ru) | 2015-09-20 |
| CA2812841A1 (en) | 2012-04-05 |
| CU24055B1 (es) | 2014-12-26 |
| WO2012041261A3 (es) | 2012-11-22 |
| WO2012041261A2 (es) | 2012-04-05 |
| AR083117A1 (es) | 2013-01-30 |
| IL225577A0 (en) | 2013-06-27 |
| CU20100186A7 (es) | 2012-06-21 |
| CO6781464A2 (es) | 2013-10-31 |
| BR112013007198A2 (pt) | 2016-06-14 |
| MX2013003545A (es) | 2013-11-04 |
| MX360726B (es) | 2018-11-13 |
| RU2013119431A (ru) | 2014-11-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101485655B (zh) | 二氢杨梅素在制备防治肿瘤放化疗不良反应的药物的应用 | |
| CA2473874C (en) | A composition for treating neurocerebrovascular disorders | |
| Dandapat et al. | Secondary metabolites from lichen Usnea longissima and its pharmacological relevance | |
| CN110464727B (zh) | 3,4-二氢-2h-苯并-[1,4]恶嗪类药物或其盐在制备抑制铁死亡药物中的应用 | |
| Jung et al. | Anti-inflammatory activity of sappanchalcone isolated from Caesalpinia sappan L. in a collagen-induced arthritis mouse model | |
| AU2011307691A1 (en) | Peptides from the venom of the Rhopalurus junceus scorpion and pharmaceutical composition | |
| Nongalleima et al. | Citrus macroptera Montruz extracts | |
| Al-Sayed et al. | Anti-inflammatory, hepatoprotective and antioxidant activity of ellagitannin isolated from Melaleuca styphelioides | |
| Mazzolin et al. | Antidiarrheal and intestinal antiinflammatory activities of a methanolic extract of Qualea parviflora Mart. in experimental models | |
| CN112409439B (zh) | 一种甘草酸衍生物、制备方法及应用 | |
| Ojeswi et al. | Protective effect of Thuja occidentalis against DMBA-induced breast cancer with reference to oxidative stress | |
| Gupta et al. | Evaluation of in vitro and invivo anti-inflammatory activities of Parthenium camphora | |
| CN106220643A (zh) | 灵芝内酯d及其药物组合物与其在制药和食品中的应用 | |
| Chandrappa et al. | In vitro anti-inflammatory activity of Carmona retusa (Vahl.) | |
| Ameen et al. | Chromatography-Spectroscopic Isolated Mo11 (Moringa oleifera) and Ms06 (Musa sapientum) Positively Immunomodulated ACE2 Levels in Blood, Kidney and Liver of Rats | |
| Moran et al. | Insect venoms and their bioactive components: A novel therapeutic approach in chronic diseases and cancer | |
| Singh et al. | Antiallergic/antiasthmatic activity of oligopeptide related to IgE | |
| KR101782962B1 (ko) | 백혈병 치료용 조성물 및 몰약 추출물의 제조방법 | |
| Ukwueze et al. | An evaluation of the analgesic and anti-inflammatory activities of the solvent fractions of Aspilia africana (pers.) | |
| CN101485791B (zh) | 显齿蛇葡萄总黄酮在制备防治肿瘤放化疗不良反应的药物的应用 | |
| JP5231244B2 (ja) | 胃炎または胃潰瘍の予防及び治療に有用なモクベツシ抽出物及びこれから分離されたモモルディカ・サポニンｉ | |
| Indrawati et al. | The Effect of an Annona muricata Leaves Extract on Circulating Soluble Adhesion Molecules in Colon Carcinogenesis Model | |
| JP5995235B2 (ja) | シガテラを治療するためのロスマリン酸及びその誘導体の使用 | |
| US20250360100A1 (en) | Anti-cancer derivatives of ovatodiolide and use thereof | |
| Ekutsu et al. | Orapuh Journal |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MK4 | Application lapsed section 142(2)(d) - no continuation fee paid for the application |